Identification	O
of	O
a	O
novel	O
cell	B-ENHANCER
type	I-ENHANCER
-	I-ENHANCER
specific	I-ENHANCER
intronic	I-ENHANCER
enhancer	I-ENHANCER
of	I-ENHANCER
macrophage	I-ENHANCER
migration	I-ENHANCER
inhibitory	I-ENHANCER
factor	E-ENHANCER
(	O
MIF	O
)	O
and	O
its	O
regulation	O
by	O
mithramycin	O
.	O


The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
genetic	O
regulation	O
of	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
.	O


DNase	O
I	O
hypersensitivity	O
was	O
used	O
to	O
identify	O
potential	O
hypersensitive	O
sites	O
(	O
HS	O
)	O
across	O
the	O
MIF	O
gene	O
locus	O
.	O


Reporter	O
gene	O
assays	O
were	O
performed	O
in	O
different	O
human	O
cell	O
lines	O
with	O
constructs	O
containing	O
the	O
native	O
or	O
mutated	O
HS	O
element	O
.	O


Following	O
phylogenetic	O
and	O
transcription	O
factor	O
binding	O
profiling	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
RNA	O
interference	O
were	O
performed	O
and	O
the	O
effects	O
of	O
incubation	O
with	O
mithramycin	O
,	O
an	O
antibiotic	O
that	O
binds	O
GC	O
boxes	O
,	O
were	O
also	O
studied	O
.	O


An	O
HS	B-ENHANCER
centred	I-ENHANCER
on	I-ENHANCER
the	I-ENHANCER
first	I-ENHANCER
intron	I-ENHANCER
of	I-ENHANCER
MIF	E-ENHANCER
was	O
identified	O
.	O


The	O
HS	S-ENHANCER
acted	O
as	O
an	O
enhancer	O
in	O
human	O
T	O
lymphoblasts	O
(	O
CEMC7A	O
)	O
,	O
human	O
embryonic	O
kidney	O
cells	O
(	O
HEK293T	O
)	O
and	O
human	O
monocytic	O
cells	O
(	O
THP	O
-	O
1	O
)	O
,	O
but	O
not	O
in	O
a	O
fibroblast	O
-	O
like	O
synoviocyte	O
(	O
FLS	O
)	O
cell	O
line	O
(	O
SW982	O
)	O
or	O
cultured	O
FLS	O
derived	O
from	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
.	O
Two	B-ENHANCER
cis	I-ENHANCER
-	I-ENHANCER
elements	I-ENHANCER
within	I-ENHANCER
the	I-ENHANCER
first	I-ENHANCER
intron	E-ENHANCER
were	O
found	O
to	O
be	O
responsible	O
for	O
the	O
enhancer	O
activity	O
.	O


Mutation	O
of	O
the	O
consensus	O
Sp1	O
GC	O
box	O
on	O
each	O
cis	B-ENHANCER
-	I-ENHANCER
element	E-ENHANCER
abrogated	O
enhancer	O
activity	O
and	O
EMSA	O
indicated	O
Sp1	O
binding	O
to	O
one	B-ENHANCER
of	I-ENHANCER
the	I-ENHANCER
cis	I-ENHANCER
-	I-ENHANCER
elements	I-ENHANCER
contained	I-ENHANCER
in	I-ENHANCER
the	I-ENHANCER
intron	E-ENHANCER
.	O


SiRNA	O
knock	O
-	O
down	O
of	O
Sp1	O
alone	O
or	O
Sp1	O
and	O
Sp3	O
together	O
was	O
incomplete	O
and	O
did	O
not	O
alter	O
the	O
enhancer	O
activity	O
.	O


Mithramycin	O
inhibited	O
expression	O
of	O
MIF	O
in	O
CEMC7A	O
cells	O
.	O


This	O
effect	O
was	O
specific	O
to	O
the	O
intronic	B-ENHANCER
enhancer	E-ENHANCER
and	O
was	O
not	O
seen	O
on	O
the	O
MIF	O
promoter	O
.	O


These	O
results	O
identify	O
a	O
novel	O
,	O
cell	B-ENHANCER
type	I-ENHANCER
-	I-ENHANCER
specific	I-ENHANCER
enhancer	I-ENHANCER
of	I-ENHANCER
MIF	E-ENHANCER
.	O


The	O
enhancer	S-ENHANCER
appears	O
to	O
be	O
driven	O
by	O
Sp1	O
or	O
related	O
Sp	O
family	O
members	O
and	O
is	O
highly	O
sensitive	O
to	O
inhibition	O
via	O
mithramycin	O
.	O
